One line in the whole PDF that caught my eyes is "Total addressable market = US$1-2bn p.a." At @ 0.685c USD, it's A$1.46 - 2.92bn.
That translates to 50c - $1 per share of INCOME PER YEAR EVERY YEAR at infinitum! And there are 6 other drug candidates in the making.
FYI - PYC has a total of 2,931,427,990 shares. At 10.5c today, and a potential to earn 50c to $1 p.a. per share, It's not rocket science that Smart Money will follow!
It's a case of whether you believe the PYC story or not. After so many years of peer reviews and now with Prof Sue Fletcher who has a brilliant track record of helping Sarepta Therapeutics making $$$ from 2 FDA approved drugs Exondys-51 and Vyondys-53 to treat DMD (Duchenne Muscular Dystrophy), there is no reason to doubt her ability to make another RNA based medicine for PycTx, code name VP-001 to treat Retinitis Pigmentosa.
DYOR!
(20min delay)